SDGRHealthcare · Health Information ServicesThe 7 Wall Street analysts covering Schrödinger, Inc. hold a median 12-month price target of $30 — +4.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Schrödinger, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Value (30): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SDGR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +4.9% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | UBS | Maintains | Neutral | $19 → $21 |
| 16 Oct 2026 | Keybanc | Maintains | Overweight | $20 → $32 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $20 → $31 |
| 12 Oct 2026 | BMO Capital | Maintains | Outperform | $24 → $30 |
| 12 Oct 2026 | BMO Capital | Maintains | Outperform | — |
| 14 Aug 2026 | UBS | Assumes | Neutral | $13 → $19 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $19 → $17 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 8 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Mar 2026 | UBS | Maintains | Neutral | — |
| 8 Jan 2026 | Keybanc | Maintains | Overweight | — |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 7 Jan 2026 | UBS | Initiates | Neutral | — |
| 15 Dec 2025 | B of A Securities | Upgrade | Buy | — |
| 8 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Neutral | — |
| 18 Aug 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Aug 2025 | Citigroup | Downgrade | Neutral | — |
| 14 Aug 2025 | Barclays | Initiates | Overweight | — |
| 14 July 2025 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SDGR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Schrödinger, Inc. returned +43.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 16% of US stocks
Cheaper than 14% of US stocks
Cheaper than 87% of US stocks
Higher than 47% of US stocks
Higher than 46% of US stocks
Higher than 68% of US stocks
Higher than 15% of US stocks
Higher than 15% of US stocks
Higher than 33% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Schrödinger, Inc. has a market value of $2.1B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $259.0M. The latest quarter grew 7.5% year on year.
Net income over the same four quarters: −$54.3M, a −21.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$130.3M.
Trailing P/E: 44.4×; forward P/E: −21.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Schrödinger, Inc. employs 850 people — $305K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Schrödinger, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Schrödinger, Inc.’s Q3 2026 earnings call; the provided text contains no further details about the discussion.
Why it matters — The transcript may provide SDGR watchers with information from the company’s quarterly earnings call, but the excerpt gives no specific topics or results.
Schrödinger raised its full-year 2026 outlook for annual contract value and drug discovery revenue after reporting third-quarter growth in software demand and revenue from therapeutics collaborations.
Why it matters — The update highlights stronger software demand and collaboration revenue alongside a higher outlook for two business metrics watched by SDGR investors.
Schrödinger reported a third-quarter loss of $0.50 per share, narrower than the Zacks consensus estimate of a $0.66 loss. The loss compares with $0.45 per share a year earlier.
Why it matters — SDGR watchers may note that the quarterly loss was smaller than the consensus estimate, while larger than the loss reported a year ago.
Schrödinger reported third-quarter 2026 results, citing 17% ACV growth and $24 million in drug discovery revenue. The company also raised its full-year ACV and drug discovery revenue outlook.
Why it matters — The reported growth and higher full-year outlook are relevant indicators of performance across Schrödinger’s software and drug discovery businesses.
Zacks says Schrodinger lacks the two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report. The item previews expectations for the report.
Why it matters — SDGR watchers may note the preview's cautious assessment of the likelihood of an earnings beat.
The 7 Wall Street analysts covering Schrödinger, Inc. have a median 12-month price target of $30, with estimates ranging from $17 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Schrödinger, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Schrödinger, Inc. 62 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Schrödinger, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +4.9% from the last close, and Ticker Nerd's factor model ranks Schrödinger, Inc. 62 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Schrödinger, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SDGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $32 over the next 12 months.
Schrödinger, Inc. returned +43.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Schrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Schrödinger, Inc.’s Q3 2026 earnings call; the provided text contains no further details about the discussion.
Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery. The company provides software tools used to model and simulate chemical and biological systems, helping researchers identify and optimize novel molecules for drug discovery and materials science. Its platform is used across the pharmaceutical, biotechnology, materials, and industrial research sectors, supporting workflows such as molecular design, simulation, and collaboration. Schrödinger also operates a drug discovery segment that applies its technology to proprietary and partnered research programs. Headquartered in New York and founded in 1990, Schrödinger plays a specialized role in the market as a provider of advanced computational chemistry solutions for scientific innovation.
CEO Dr. Ramy Farid Ph.D. · 850 employees · United States · https://www.schrodinger.com
